N/A
Completed N=10,398
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Pentoxifylline Versus Cilostazol
Source: ClinicalTrials.gov NCT05635370 ↗Enrolled (actual)
10,398
Serious AEs
—
Results posted
Aug 2025
Primary outcomePrimary: Time to Dementia Onset — 28.1; 32.6; 37.9; 44.8 Incidence rate per 1000 person year
Summary
This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Time to Dementia Onset |
28.1; 32.6; 37.9; 44.8; 30.8; 43.9 | — |
Eligibility Criteria
Please see https://docs.google.com/spreadsheets/d/17QJ294pffmOCFYLeq0eSvn7hlj6MOb-0dJCr1RL3kfk/edit?usp=sharing or Appendix A (https://drive.google.com/drive/folders/1-lR6dR\_aP44GoryjCad\_NwRhjPpsIKDU?usp=sharing) for full code and algorithm definitions.
Medicare timeframe: 2008 to 2018 (end of data availability)
Inclusion Criteria
- 1. Aged >/= 65 years on the index date
- 2. Enrollment in Medicare Part A, B, and D with no HMO coverage for 365 days prior to and including cohort entry date
- 3. At least two claims with peripheral artery disease diagnosis measured 365 days prior to drug initiation
Exclusion Criteria
- 1. Prior history of dementia measured anytime prior to cohort entry date
- 2. Prior history of nursing home admission in the 365 days prior to the cohort entry date
- 3. Prior history of Pentoxifylline or Cilostazol use anytime prior to cohort entry date
Data sourced from ClinicalTrials.gov (NCT05635370). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.